Physicochemical Stability of Generic Thiotepa Concentrate and Ready-to-Administer Infusion Solutions for Conditioning Treatment

Author:

Linxweiler Helen,Thiesen Judith,Krämer Irene

Abstract

The objective of this study was to determine the physicochemical in-use stability of recently approved Thiotepa Riemser concentrate in the original vial and diluted ready-to-administer (RTA) infusion solutions in prefilled glucose 5% and 0.9% NaCl polyolefin bags. Thiotepa Riemser 10 mg/mL concentrates and infusion solutions (1 mg/mL, 2 mg/mL, 3 mg/mL) were prepared in triplicate and stored at 2–8 °C or 25 °C for 14 days. Thiotepa concentrations were determined using a stability-indicating RP-HPLC assay. In parallel, pH and osmolality were measured. Sub-visible particles were counted on day 0 and 14. Thiotepa Riemser concentrate was revealed to be stable for 14 days when stored at 2–8 °C, or for 24 h when stored at 25 °C. Thiotepa concentrations in infusion solutions stored at 2–8 °C remained above 95% of the initial concentrations for at least 14 days, regardless of the type of vehicle solution. When stored at 25 °C, thiotepa infusion solutions in glucose 5% proved to be physicochemically stable for 3 days (1 mg/mL), 5 days (2 mg/mL) or 7 days (3 mg/mL). Thiotepa infusion solutions in 0.9% NaCl remained physicochemically stable for 5 days (1 mg/mL) or 7 days (2 mg/mL, 3 mg/mL). At these points in time, the specification limit of ≤0.6% monochloro-adduct was fulfilled. In parallel, an elevation of the pH values was registered. Thiotepa concentrates and infusion solutions should be stored at 2–8 °C due to temperature-dependent physicochemical stability, and for microbiological reasons. Glucose 5% infusion solution is recommended as a diluent, and stability-improving nominal 2 mg/mL to 3 mg/mL thiotepa concentrations should be obtained.

Funder

Esteve Pharmaceuticals GmbH

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference21 articles.

1. Chemistry, pharmacology and pharmacokinetics of N,N′,N″-triethylenethiophosphoramide (ThioTEPA);Smeets;Cancer Treat. Rev.,2000

2. European Medicines Agency (2022, January 13). Thiotepa Riemser: Summary of Product Characteristics in EPAR-Product Information. Available online: https://www.ema.europa.eu/en/documents/product-information/thiotepa-riemser-epar-product-information_en.pdf.

3. European Medicines Agency (2022, January 13). Assessment Report Thiotepa Riemser EMA/129214/2021. Available online: https://www.ema.europa.eu/en/documents/assessment-report/thiotepa-riemser-epar-public-assessment-report_en.pdf.

4. Lederle Arzneimittel GmbH & Co. (1995). Thiotepa “Lederle“ 15 mg Prescribing Information, Lederle Arzneimittel GmbH & Co.

5. Stability of thiotepa (lyophilized) in 5% dextrose injection at 4 and 23 °C;Xu;Am. J. Health-Syst. Pharm.,1996

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3